GLP-1 for Weight Loss: Market Surge Driven by 60%+ Efficacy and Novo Nordisk Dominance
Published: 12 7 月, 2026 19:57
Author: Matthew Mercier
Abstract: The GLP-1 weight loss market is surging, driven by 60%+ efficacy in clinical trials and Novo Nordisk’s dominance (Wegovy/Ozempic). This analysis contrasts leading brands (Eli Lilly’s tirzepatide vs. semaglutide) on pharmacokinetics, side-effect profiles, and manufacturing complexity. Key differentiators include peptide stability, dosing frequency, and cold-chain logistics. Market trends show a shift toward oral formulations and biosimilars, with regulatory certifications (FDA, EMA) critical for supplier selection. The sector’s 30%+ CAGR underscores demand for high-purity APIs and robust quality management systems.